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A major problem in diagnosing sporadic cerebral amy-loid angiopathy (sCAA) is the absence of reliable, non-
invasive diagnostic tests. Hereditary cerebral hemorrhage 
with amyloidosis-Dutch type (HCHWA-D) is an autosomal 
dominant disease, and the chemical composition and under-
lying pathology of the amyloid deposits is similar to that in 
sCAA.1 Clinically, the symptomatic stage of both sCAA and 
HCHWA-D is characterized by recurrent hemorrhagic strokes 
and cognitive impairment,2 and common radiological mani-
festations are microbleeds, intracerebral hemorrhages, super-
ficial siderosis, convexity subarachnoid hemorrhages,3 greater 
volumes of white matter hyperintensities (WMHs),4,5 and 
microinfarcts.6 Because sCAA and HCHWA-D are subtypes 
of small-vessel disease, other small-vessel disease markers 
such as lacunar infarcts and dilated perivascular spaces might 
also be more prevalent in sCAA and HCHWA-D. Previous 
studies suggested that in patients with sCAA and HCHWA-D, 
cognitive impairment may also be an early disease marker, 
preceding stroke or any other brain lesion.2,7 The goal of 
our study is to identify which markers are an early sign of 
HCHWA-D using the most sensitive magnetic resonance 
imaging (MRI) techniques at 3T and 7T and to assess whether 
cognitive decline and neuropsychiatric abnormalities are an 
early sign of the disease.
Materials and Methods
HCHWA-D and control subjects were recruited via the HCHWA-D 
patient association in Katwijk (the Netherlands) and outpatient clinic 
of the Department of Neurology of the Leiden University Medical 
Center. Twenty-seven DNA-proven HCHWA-D mutation carriers and 
33 controls were included (symptomatic [n=15] and presymptomatic 
[n=12] mutation carriers). Subjects were considered symptomatic 
when they had experienced signs of the disease reported to a general 
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practitioner. At 7T, T2*-weighted gradient-echo scans and fluid-atten-
uated inversion recovery sequences were performed. At 3T, fluid-
attenuated inversion recovery, T1-weighted images, and T2-weighted 
images were acquired. Microbleeds, intracerebral hemorrhages, 
superficial siderosis, and convexity subarachnoid hemorrhages were 
assessed at 7T T2*-weighted sequences. Cortical microinfarcts were 
scored as previously described.8 Because counting microinfarcts is a 
relatively new technique, these lesions were scored by 2 independent 
experienced raters, and inter-rater reliability was calculated. At 3T, 
WMHs, dilated perivascular spaces in the basal ganglia and centrum 
semiovale, and lacunar infarcts were assessed. A battery of neuro-
psychological and neuropsychiatric tests was performed (online-only 
Data Supplement).
Statistics
Mann–Whitney U testing was used to assess differences in age 
between groups, univariate general linear modeling analysis was 
used to assess differences in blood pressure measurements, adjusted 
for age and sex, and χ2 tests were used to assess differences in sex, 
educational level, and percentage cardiovascular risk factors between 
groups. For assessment of microinfarcts, interobserver variability was 
calculated. Univariate general linear modeling analysis was used to 
assess the association between MRI markers and cognitive perfor-
mance on the one hand and on the other, mutation status, adjusted for 
age, sex, and education (online-only Data Supplement).
Results
The characteristics of the presymptomatic mutation carriers 
and symptomatic mutation carriers versus controls are shown 
in Table I in the online-only Data Supplement. All symptom-
atic patients clinically experienced one or multiple strokes as 
first symptomatic sign of the disease. None of the symptom-
atic patients experienced objective cognitive impairment as 
first sign of the disease. None of the presymptomatic mutation 
Table 1.  MRI Markers in Presymptomatic and Symptomatic Mutation Carriers Versus Controls
MRI Markers
Controls (n=33) Presymptomatic Carriers (n=12) Symptomatic Carriers (n=15)
Prevalence
Median
(25th–75th Percentile) Prevalence
Median
(25th–75th Percentile) Prevalence
Median
(25th–75th Percentile)
Microbleeds 6.7% (2/30) 0 (0–0) 18.2% (2/11) 0 (0–0) 100% (15/15)* 49 (28–118)*
ICHs 0% (0/30) 0 (0–0) 9.1% (1/11) 0 (0–0) 100% (14/14)* 13 (5–27)*
Convexity SAHs 0% (0/30) 0 (0–0) 18.2% (2/11) 0 (0–0) 50% (7/14)* 0.5 (0–2.3)*
Siderosis (%) 0% (0/30) … 9.1% (1/11) … 93.3% (14/15)* …
Cortical microinfarcts  
(mean, range)
13.8% (4/29) 0.2 (0–2) 30.0% (3/10)† 0.8 (0–6) 100% (12/12)* 5 (2–13)*
WMHs volume (cm3) … 0.6 (0.2–2.2) … 1.4 (0.4–6.0)* … 82.4 (50.7–133.0)*
DPVS-CSO … 3 (2–3) … 3 (2–4) … 4 (3–4)†
DPVS-BG … 2 (2–2) … 2 (2–2) … 2 (2–2)
Lacunar infarcts 32.3% (10/31) 0 (0–1) 27.3% (3/11) 0 (0–1) 13.3% (2/15)* 0 (0–0)
BG indicates basal ganglia; CSO, centrum semiovale; DPVS, dilated perivascular spaces; ICH, intracerebral hemorrhage; MRI, magnetic resonance imaging; and SAH, 
subarachnoid hemorrhage.
*P<0.001, controls vs presymptomatic carriers and controls vs symptomatic carriers.
†P<0.05, controls vs presymptomatic carriers and controls vs symptomatic carriers.
Figure. Graphs of (A) intracerebral hemor-
rhages (ICHs), (B) microbleeds, (C) microin-
farcts, and (D) white matter hyperintensity 
(WMH) volume against age in the 3 different 
groups.
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carriers reported cognitive complaints or showed objective 
cognitive impairment.
The κ value for interobserver agreement was almost per-
fect for detecting presence of cortical microinfarcts, κ=0.88 
(P<0.001). The prevalence and median count of microbleeds, 
intracerebral hemorrhages, convexity subarachnoid hemor-
rhages, superficial siderosis, microinfarcts, median volume of 
WMHs, and dilated perivascular spaces-centrum semiovale 
are significantly higher in the symptomatic mutation carriers 
than in controls, adjusted for age and sex (P<0.05; Table 1). In 
presymptomatic mutation carriers, the prevalence of microin-
farcts (P=0.044) and median volume of WMHs (P=0.000) is 
significantly increased compared with controls adjusted for age 
and sex. As illustrated in Figure, our cross-sectional data sug-
gest that patients start developing changes on MRI at ≈5 years 
before developing their first symptoms (at age of 45 years).
All cognitive tests were performed significantly worse by 
symptomatic mutation carriers than controls, adjusted for age, 
sex, and education (P<0.05). They also showed a higher score 
on the Hospital Anxiety and Depression Scale (HADS) anxiety 
and depression scale (P<0.05). Presymptomatic mutation car-
riers did not show any significant differences compared with 
controls on the cognitive and neuropsychiatric tests (Table 2).
Discussion
Of all sCAA markers, WMHs and cortical microinfarcts 
(ischemic manifestations of CAA) are more prevalent among 
presymptomatic subjects and precede cognitive and neuropsy-
chiatric symptoms and intracerebral hemorrhages, whereas 
other sCAA MRI-related markers are only more prevalent in 
symptomatic patients. Microinfarcts are a new finding likely 
related to the fact that 7T MRI was not available in previ-
ous studies. Although it has been suggested that in sCAA 
amyloid-β deposition alone could cause cognitive impair-
ment7 and that in HCHWA-D mutation carriers cognitive 
deterioration can precede the first clinical stroke,2 we showed 
that cognitive abnormalities are not present in presymptom-
atic subjects with HCHWA-D. The generalizability of these 
findings to sCAA remains to be established because it occurs 
in older individuals in whom there is a closer association with 
amyloid plaques and the clinical features of Alzheimer dis-
ease. Using the most sensitive MRI techniques for all lesions, 
we found several abnormal MRI characteristics in the pres-
ymptomatic phase but no cognitive deficits suggesting that 
HCHWA-D starts with abnormalities in the brain caused by 
amyloid-β deposition, which then causes cognitive deficits.
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Cognitive Domain Cognitive Tests
Controls (n=33)
(SD; Range)
Presymptomatic Mutation 
Carriers (n=12)
(SD; Range)
Symptomatic Mutation  
Carriers (n=15)
(SD; Range)
Global cognitive function MMSE (mean points) 29.4 (0.7; 27–30) 29.8 (0.6; 28–30) 26.7 (3.8; 16–30)*
Memory WMS (mean memory quotient) 124.9 (10.8; 105–143) 121.6 (11.5; 103–137) 110.5 (24.9; 72–143)†
 HVLT immediate recall 28.2 (4.3; 16–35) 28.0 (2.8; 24–32) 21.4 (7.5; 7–31)†
 HVLT delayed recall 10.4 (2.3; 6–19) 9.8 (1.7; 7–12) 6.8 (3.7; 0–12)*
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Executive function TMT B (mean s) 59.9 (22.5; 30–105) 54.5 (13.4; 39–85) 161.2 (127.1; 67–540)*
 DSST (mean nr of correct symbols) 77.1 (15.5; 46–110) 84.0 (11.8; 62–101) 47.3 (17.3; 18–79)*
 Clock drawing (median points) 3.0 (0.2; 2–3) 3.0 (0.5; 2–3) 2.0 (0.6; 1–3)*
Language Letter fluency (mean nr of correct words) 33.9 (9.1; 13–50) 32.9 (11.8; 19–54) 23.5 (7.9; 12–38)†
 Category fluency (mean nr of correct words) 22.2 (5.6; 14–40) 23.0 (6.0; 14–32) 15.3 (5.5; 3–23)†
 BNT (mean nr of correct items) 28.6 (1.0; 27–30) 28.3 (1.1; 26–30) 23.0 (6.6; 4–29)*
Apathy Apathy scale of Starkstein (mean points) 9.4 (3.7; 2–15) 8.9 (5.2; 2–20) 8.9 (4.9; 2–18)
Anxiety HADS subscale anxiety (mean points) 3.5 (2.7; 0–10) 4.0 (2.8; 0–9) 5.5 (3.8; 0–13)†
Depression HADS subscale depression (mean points) 1.9 (2.3; 0–9) 1.8 (3.0; 0–10) 4.1 (3.2; 0–11)†
BNT indicates Boston Naming Test; DSST, Defense Activity for Non-Traditional Education Support (DANTES) Subject Standardized Test; HADS, Hospital Anxiety and 
Depression Scale; HVLT, Hopkins Verbal Learning Test; MMSE, Mini-Mental State Examination; nr, number; TMT, Trail Making Test; and WMS, Wechsler Memory Scale.
*P<0.001, controls vs presymptomatic carriers and controls vs symptomatic carriers.
†P<0.05, controls vs presymptomatic carriers and controls vs symptomatic carriers.
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Supplemental Methods 
Participants 
Subjects were selected via the HCHWA-D patient association in Katwijk (the Netherlands) 
and the outpatient clinic of the Department of Neurology of the Leiden University Medical 
Center based on DNA analysis for confirmation of codon 693 mutation in the amyloid-β 
precursor protein (AβPP) gene. Twenty-seven DNA-proven HCHWA-D mutation carriers 
were included in the present study. These subjects had a mean age of 45.9 years (25th -75th 
percentile 35 to 55 years). Seventeen of them were female (mean age 44.4 years, 25th -75th 
percentile 33 to 53 years) and ten male (mean age of 48.4 years, 25th -75th percentile 34 to 58 
years). Both symptomatic (n=15) and pre-symptomatic (n=12) mutation carriers were 
included. Subjects were considered symptomatic when they had experienced signs of the 
disease reported to a general practitioner. Control subjects were recruited from individuals at 
risk for HCHWA-D (one of the parents has HCHWA-D) but who tested genetically negative 
and from subject spouses, family or friends, who also underwent genetic testing for inclusion. 
All controls were ascertained to be both stroke-free as well as negative genetic tested. Thirty-
three controls were included in the present study. These subjects had a mean age of 45.6 
years (25th -75th percentile 34 to 57 years). Twenty of them were female (mean age 41.9 
years, 25th -75th percentile 32 to 52 years) and thirteen male (mean age of 51.3 years, 25th -
75th percentile 41 to 61 years). The ethics committee of our institution approved the study, 
and written informed consent was obtained from all subjects. 
 
MRI 
Image acquisition 
All participants underwent a 7T and 3T MRI scan. 7T MRI was performed on a whole body 
human MRI system (Philips Healthcare, Best, the Netherlands) using a quadrature transmit 
and 32-channel receive head coil. 2D flow-compensated transverse T2*-weighted gradient-
echo scan was performed with repetition time (TR)/echo time (TE) 794/25 ms, flip angle 45°, 
slice thickness 1.0 mm with a 0.1 mm interslice gap, 50 slices and coverage of 10 cm, 240 x 
180 x 22 mm field of view (FOV), 1000 x 1024 matrix size – spatial resolution of 0.24 x 0.24 
mm2 ~ scan duration 20 minutes.1 3D magnetization prepared sagittal fluid attenuated 
inversion recovery (FLAIR) sequence was performed with TR/TE/inversion time (TI) 
8000/300/2200 ms, flip angle 100°, slice thickness 1 mm, with 1 mm3 isotropic voxels, scan 
duration ~ 8 minutes.2 At 3T FLAIR scans were performed with: TR/TE: 11.0s/125ms, flip 
angle 90°, slices 25, FOV 252x179.76x250mm, matrix size 224x224, scan duration ~ 5 
minutes. 3D T1-weighted images were acquired with: TR/TE 9/4.6ms, flip angle 8°, FOV = 
224×177×168mm, scan duration ~5 minutes. T2-weighted images were acquired with: 
TR/TE: 4.2s/ 80ms, flip angle 90°, 40 slices, FOV 224x180x144 mm, slice thickness 3.6 mm, 
matrix size 448x320 and scan duration ~3 minutes.  
 
Image analysis 
To be as sensitive and precise as possible for all lesions scored in this study, two different 
field strengths (7T and 3T) and the best validated methods were used per lesion. The 
detection of hemorrhagic lesions (microbleeds, ICHs, convexity SAHs and superficial 
siderosis) was evaluated at 7T T2*-weighted sequences as this field strength and sequence is 
3 
 
most sensitive for these lesions. Lobar microbleeds (location as described by the Boston 
criteria3) were defined and scored as previously described.4 Only remote, resorbed ICHs were 
observed and they were defined as parenchymal defects with evidence of hemosiderin in their 
wall. The number and presence of convexity SAHs was assessed described as a subarachnoid 
bleeding localized to the convexities of the brain.5 The presence of superficial siderosis was 
assessed described as linear residues of blood in the superficial layers of the cortex.6 The 
number and presence of cortical microinfarcts were scored on 7T FLAIR images as 
previously described, as these lesions are visualized best using this field strength and 
sequence.7 Since counting microinfarcts is a relatively new technique, these lesions were 
scored by two independent experienced raters and interrater reliability was calculated. WMHs 
are defined and analysed using 3T FLAIR images as described earlier using a semi-
automated and validated method.8 DPVS were evaluated and assessed in the basal ganglia 
(BG) and centrum semiovale (CSO) on 3T T2-weighted and T1-weighted images. DPVS are 
defined and rated according to a 4-point semi-quantitative score.9 Presence of lacunar infarcts 
was assessed using 3T T2-weighted and FLAIR images as described earlier.10 
 
Cognitive and neuropsychiatric function 
A battery of neuropsychological tests measuring global cognitive functioning (Mini mental 
state examination (MMSE)11), memory (Wechsler Memory Scale (WMS)12 and Hopkins 
Verbal Learning Test (HVLT)13), psychomotor speed (Trailmaking test (TMT) part A), 
executive function (TMT part B (cognitive flexibility)14, Digit symbol substitution test 
(DSST) of the WAIS III15 and Clock drawing), and language (letter and animal naming (letter 
and category fluency)16 and Boston naming test (BNT)17) were performed. Also 
neuropsychiatric tests were performed measuring apathy (Apathy scale of Starkstein)18, 
anxiety (hospital anxiety and depression scale (HADS)19) and depression (HADS).  
 
Statistics 
Mann-Whitney U-testing was used to assess differences in age between groups, univariate 
general linear modeling analysis was used to assess differences in blood pressure 
measurements between groups, adjusted for age and sex, and chi-square tests were used to 
assess differences in sex, educational level and percentage cardiovascular risk factors 
between groups. For counting microinfarcts, the interobserver variability (kappa value) was 
calculated and the grading of interobserver agreement was performed according to the 
recommendations of Landis and Koch.20 Univariate general linear modeling analysis was 
used to assess the association between the prevalence and median of MRI markers (for MRI 
markers (except cortical microinfarcts) natural log transformation was used because of a non-
normal distribution) and mutation status, adjusted for age and sex. Univariate general linear 
modeling analysis was also used to assess the association between cognitive and 
neuropsychiatric tests and mutation status, adjusted for age, sex and. All statistical analyses 
were performed with the Statistical Package of Social Sciences (SPSS, version 20.0; SPSS, 
Chicago, Ill). 
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Supplemental Tables 
Table I: Baseline characteristics of pre-symptomatic and symptomatic mutation carriers 
versus controls  
 Controls 
(SD; 25th-75th 
percentile) 
(N=33) 
Pre-symptomatic 
carriers (SD; 25th-
75th percentile) 
(N=12)) 
Symptomatic carriers 
(SD; 25th-75th 
percentile) 
(N=15) 
Age (years) 45.6 (14.1; 34–57) 34.3 (12.1; 23–47)* 55.1 (5.2; 51–60)* 
Sex (male/female) 13/20 3/9 7/8 
Education (median) Associate’s degree Bachelor’s degree Associate’s degree 
Systolic blood pressure 130.6 (26.1; 109 – 142) 125.2 (14.4; 112 – 133) 144.2 (19.8; 129 – 168) 
Diastolic blood pressure 81.5 (12.2;72 – 87) 80.4 (9.4; 73 – 87) 89.1 (10.4; 78 – 96) 
Mean arterial pressure 97.6 (15.9; 86 – 107) 95.3 (9.4; 88 – 102) 107.5 (12.4; 95 – 117) 
Pulse pressure 49.1 (18.4; 36 – 60) 44.8 (13.2; 33 – 50) 55.1 (14.7; 43 – 69) 
Hypertension (%) 18.2 0 40 
Hyperlipidemia (%) 6.1 0 33.3* 
Diabetes Mellitus (%) 0 8.3 6.7 
Cardiovascular disease (%) 0 0 6.7 
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